"I am looking forward to attending the 3 day-meeting to learn about the latest technological innovations in the field of food allergy. The attendance of industry leading speakers will be a key opportunity for networking!"
Sophie Nutten, Science Lead, Allergy, Nestle
"The landmark approval of Palforzia by the US FDA will have a lasting impact on the lives of those living with peanut allergy. At the same time, it has validated the urgent need for food allergy therapeutics. I am thrilled for the opportunity to work with other leading experts to shape the future of food allergy therapy through the inaugural Next Generation Food Allergy Drug Development meeting."
Edwin Kim, Associate Professor of Medicine & Pediatrics, University of North Carolina School of Medicine
"It will be a great opportunity to learn about upcoming developments in food allergy management. It will also be an opportunity to introduce our novel drug development program for peanut allergy treatment."
Kemi Oluwayi, Head of Clinical Science, Allergy Therapeutics
"I'm looking forward to the Next Generation Food Allergy Drug Development Meeting because of the sheer paucity of FDA/ EMA approved therapeutic solutions in this niche, let alone grossly efficacious ones, and the exciting pipelines which a few companies have in this arena, including Intrommune. These pipelines might help address the high unmet patient need area of food allergies with a potentially high degree of safety and inducing a robust desensitization paradigm towards mitigation of anaphylaxis and need for emergency epinephrine administration."
Abhit Singh, VP, Medical Affairs, Intrommune